Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R | Q15722 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.43 |
| ▸ | HCAR2 | Q8TDS4 | 12/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | MME | P08473 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7591697 | 0.83 | LTB4R (0.48) | LTB4RFFAR1AKR1B1HCAR2RAB9A | |
| SCHEMBL7600452 | 0.78 | LTB4R (0.48) | LTB4RFFAR1RAB9AGAAMAPT | |
| SCHEMBL7591701 | 0.77 | LTB4R2 (0.41) | FFAR1AKR1B1MME | |
| SCHEMBL6170130 | 0.75 | MAPT (0.48) | LTB4RFFAR1AKR1B1RAB9AGAA | |
| SCHEMBL5303240 | 0.75 | RAB9A (0.56) | FFAR1AKR1B1HCAR2RAB9AMME | |
| SCHEMBL7596215 | 0.74 | ALDH1A1 (0.51) | LTB4RMAPTPOLBLMNA | |
| SCHEMBL5298682 | 0.73 | HCAR2 (0.54) | FFAR1AKR1B1HCAR2RAB9AMME | |
| SCHEMBL7916874 | 0.72 | HCAR3 (0.59) | RAB9AGAAMAPTPOLBSMN1; SMN2 | |
| SCHEMBL7593521 | 0.70 | ALDH1A1 (0.47) | GAAMAPTPOLBSMN1; SMN2LMNA | |
| SCHEMBL7591464 | 0.70 | LTB4R (0.51) | LTB4RHCAR2RAB9AGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020082280-A1 | Method of inhibiting neoplastic cells with benzimidazole derivatives | OSI PHARMACEUTICALS, INC. | 2002-06-27 | — | — | US | disclosed |
| US-6348032-B1 | POTENT COMPOUNDS THAT INDUCE APOPTOSIS IN NEOPLASTIC CELLS (BUT NOT SUBSTANTIALLY IN NORMAL CELLS), WITHOUT SUBSTANTIALLY INHIBITING PGE-2. | CELL PATHWAYS, INC. | 2002-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082280-A1 | Method of inhibiting neoplastic cells with benzimidazole derivatives | MKI67, CCNI, TMBIM6 | LTB4R 1803/4885FFAR1 4696/4885AKR1B1 1698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.